Skip to content

uniQure QURE Dutch Sites — PP&E (Net)

Other geography segments

Lexington Us
$461K-36.8%
Other
$185K-19.9%

Similar metrics at other companies

Enerpac Tool Group logo
EPACNETHERLANDS — Property, plant & equipment, net
$2.92M+14.8%
Celanese Corporation logo
CEThe Netherlands — Property, plant and equipment, net
$57M+16.3%
Impinj, Inc. logo
PIOthers Countries — PP&E (Net)
$5.22M-31.2%
Euronet Worldwide logo
EEFTNL — PP&E (Net)
$4.5M+9.8%
Kiniksa Pharmaceuticals International, plc logo
KNSAOutside United States And United Kingdom — PP&E (Net)
$433K
Vishay Precision Group logo
VPGEurope — PP&E (Net)
$5.2M+1.2%

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: uniQure’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's dutch sites — pp&e (net).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's dutch sites — PP&E (net)?
uniQure (QURE) reported dutch sites — PP&E (net) of $13.15M in Q4 2025.
What does dutch sites — PP&E (net) mean?
This metric represents the net book value of tangible assets, such as laboratory facilities, manufacturing equipment, and research infrastructure, located within the company's Dutch operational sites. It reflects the capital investment dedicated to the firm's primary gene therapy research and production hub in the Netherlands. Monitoring this value helps investors assess the scale of physical infrastructure supporting the company's core R&D and clinical supply chain capabilities.